The fluorescent ligands showed high variability in depicting tau pathology across Alzheimer’s disease cases, despite all cases having reached Braak & Braak stage VI and Thal phase 5. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.